# US 2013/0259848 A1 · Enzyme combinations to reduce brain tissue swelling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259848 A1
- Document ID: US20130259848A1
- Status: Published application
- Kind: A1
- Application number: 13/900,755
- Filed: 2013-05-23
- Published: 2013-10-03
- Earliest claimed: 2010-11-23
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Benjamin Simon ELKIN; Barclay MORRISON, III; John Desmond Finan
- Web page: https://patentgrep.com/patent/US20130259848A1

## CPC

- A61K 38/54: Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A61K 38/46: Hydrolases (3)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/51: Lyases (4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure.

## Claims

### Claim 1

A method of reducing brain tissue swelling, comprising the step of contacting the brain tissue with a composition comprising enzymes that reduce fixed charge density of the brain tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the enzymes digest chondroitin sulfate proteoglycans or heparin sulfate proteoglycans.

### Claim 3 (depends on 2)

The method of claim 2, wherein the enzyme that digests chondroitin sulfate proteoglycans is chondroitinase ABC.

### Claim 4 (depends on 2)

The method of claim 2, wherein the enzyme that digests heparin sulfate proteoglycans is heparinase.

### Claim 5 (depends on 4)

The method of claim 4, wherein the heparinase is heparinase I and heparinase III.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition further comprises enzyme that digests DNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the enzyme that digests DNA is DNase I.

### Claim 8

A method of reducing brain tissue swelling in a subject, comprising the step of administering to the subject a composition comprising enzymes that reduce fixed charge density of the brain tissue.

### Claim 9 (depends on 8)

The method of claim 8, wherein the enzymes digest chondroitin sulfate proteoglycans or heparin sulfate proteoglycans.

### Claim 10 (depends on 9)

The method of claim 9, wherein the enzyme that digests chondroitin sulfate proteoglycans is chondroitinase ABC.

### Claim 11 (depends on 9)

The method of claim 9, wherein the enzyme that digests heparin sulfate proteoglycans is heparinase.

### Claim 12 (depends on 11)

The method of claim 11, wherein the heparinase is heparinase I and heparinase III.

### Claim 13 (depends on 8)

The method of claim 8, wherein the composition further comprises enzyme that digests DNA.

### Claim 14 (depends on 13)

The method of claim 13, wherein the enzyme that digests DNA is DNase I.
